"Hydroxyurea" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antineoplastic agent that inhibits DNA synthesis through the inhibition of ribonucleoside diphosphate reductase.
Descriptor ID |
D006918
|
MeSH Number(s) |
D02.948.395
|
Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Hydroxyurea".
Below are MeSH descriptors whose meaning is more specific than "Hydroxyurea".
This graph shows the total number of publications written about "Hydroxyurea" by people in this website by year, and whether "Hydroxyurea" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 0 | 1 | 1 |
1995 | 0 | 2 | 2 |
1996 | 1 | 3 | 4 |
1997 | 3 | 3 | 6 |
1998 | 3 | 4 | 7 |
1999 | 2 | 3 | 5 |
2000 | 0 | 5 | 5 |
2001 | 0 | 4 | 4 |
2002 | 2 | 2 | 4 |
2003 | 1 | 4 | 5 |
2004 | 0 | 6 | 6 |
2006 | 1 | 3 | 4 |
2007 | 1 | 0 | 1 |
2008 | 0 | 1 | 1 |
2009 | 0 | 2 | 2 |
2010 | 1 | 0 | 1 |
2011 | 4 | 2 | 6 |
2012 | 1 | 1 | 2 |
2013 | 2 | 3 | 5 |
2014 | 2 | 1 | 3 |
2015 | 2 | 3 | 5 |
2016 | 3 | 2 | 5 |
2017 | 0 | 2 | 2 |
2018 | 3 | 1 | 4 |
2019 | 4 | 3 | 7 |
2020 | 2 | 6 | 8 |
2021 | 1 | 0 | 1 |
2022 | 1 | 6 | 7 |
2023 | 0 | 4 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Hydroxyurea" by people in Profiles.
-
Moving toward disease modification in polycythemia vera. Blood. 2023 11 30; 142(22):1859-1870.
-
Biallelic variants in CRIPT cause a Rothmund-Thomson-like syndrome with increased cellular senescence. Genet Med. 2023 Jul; 25(7):100836.
-
Hyperextended telomeres promote formation of C-circle DNA in telomerase positive human cells. J Biol Chem. 2023 05; 299(5):104665.
-
Screening for asthma in preschool children with sickle cell disease. J Asthma. 2023 09; 60(9):1787-1792.
-
Pulmonary hypertension screening in children with sickle cell disease. Pediatr Blood Cancer. 2023 Jan; 70(1):e29980.
-
SURPASS-ET: phase III study of ropeginterferon alfa-2b versus anagrelide as second-line therapy in essential thrombocythemia. Future Oncol. 2022 Sep; 18(27):2999-3009.
-
Sickle Cell Disease: A Review. JAMA. 2022 07 05; 328(1):57-68.
-
Cases in the management of polycythemia vera: switching from hydroxyurea to ruxolitinib to resolve symptoms and improve quality of life. Clin Adv Hematol Oncol. 2022 06; 20 Suppl 11(6):1-12.
-
Urgent cytoreduction for newly diagnosed acute myeloid leukemia patients allows acquisition of pretreatment genomic data and enrollment on investigational clinical trials. Am J Hematol. 2022 07; 97(7):885-894.
-
Hyperleukocytosis and leukostasis in acute and chronic leukemias. Leuk Lymphoma. 2022 08; 63(8):1780-1791.